Organogenesis (NASDAQ:ORGO) Trading Up 1.7% – Here’s Why

Organogenesis (NASDAQ:ORGO) shares traded up 1.7% during trading on Monday . The stock traded as high as $2.46 and last traded at $2.39. 1,113,586 shares were traded during trading, a decline of 50% from the average session volume of 2,232,015 shares. The stock had previously closed at $2.35.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Weiss Ratings raised Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday, February 27th. Wall Street Zen raised Organogenesis from a “hold” rating to a “buy” rating in a research note on Sunday, March 8th. Finally, BTIG Research reiterated a “buy” rating and issued a $8.00 target price on shares of Organogenesis in a report on Thursday, March 26th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Organogenesis presently has an average rating of “Moderate Buy” and an average target price of $8.50.

Organogenesis Price Performance

The firm has a market cap of $307.45 million, a P/E ratio of 29.88 and a beta of 1.48. The company has a quick ratio of 3.32, a current ratio of 3.62 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average is $2.73 and its two-hundred day moving average is $3.95.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. The business had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million.

Insider Activity at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were bought at an average price of $2.67 per share, for a total transaction of $26,700.00. Following the transaction, the director directly owned 225,707 shares in the company, valued at approximately $602,637.69. This trade represents a 4.64% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 33.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently added to or reduced their stakes in the business. Quarry LP bought a new position in shares of Organogenesis during the 3rd quarter worth approximately $25,000. State of Alaska Department of Revenue bought a new stake in shares of Organogenesis in the 3rd quarter valued at $25,000. Flagship Harbor Advisors LLC bought a new stake in shares of Organogenesis in the 4th quarter valued at $34,000. Federated Hermes Inc. lifted its position in shares of Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after acquiring an additional 2,953 shares during the period. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Organogenesis during the 4th quarter valued at $57,000. 49.57% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.